Drug intelligence / Profile preview

etanercept + vedolizumab

Development stage: Preclinical
Lead developer: Takeda
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

A combination therapy of etanercept (a TNF inhibitor) and vedolizumab (an α4β7 integrin inhibitor) used primarily for patients with concurrent inflammatory bowel disease (IBD) and spondyloarthritis (SpA). This dual biological therapy approach addresses situations where vedolizumab effectively controls intestinal inflammation but fails to manage joint symptoms, or where anti-TNF therapy has lost effectiveness for IBD but remains effective for SpA.

Targets

TNFA (Tumor necrosis factor alpha (soluble))α4β7 (Integrin alpha-4 beta-7 heterodimer)

Beyond the preview

Go deeper on etanercept + vedolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etanercept + vedolizumab.

Explore the full profile